Nektar Therapeutics (NASDAQ:NKTR) is among the hottest SMID-cap stocks so far in 2025. On November 10, Oppenheimer analyst Jay Olson reaffirmed his Outperform rating on Nektar Therapeutics ...
Morning Overview on MSNOpinion
The AI investment wave could trigger a 2008 style shock
The AI boom is being sold as a once‑in‑a‑generation revolution, but the scale and speed of the money rushing in now look ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback